INCYTE CORP (INCY) Stock News
NASDAQ:INCY - Nasdaq - US45337C1027 - Common Stock - Currency: USD
INCY Latest News, Press Relases and Analysis
INCYTE CORP (NASDAQ:INCY) – A Potential Undervalued Opportunity in Biotech
INCYTE CORP (NASDAQ:INCY) presents a compelling value case with strong profitability, low debt, and an attractive valuation. The biotech firm's fundamentals suggest potential upside for long-term investors.
Specialised Therapeutics announces expanded partnership with Incyte
Specialised Therapeutics announced the expansion of its existing supply and distribution agreement with Incyte (INCY) Biosciences International Sarl, the Swiss-based affiliate of Incyte, to launch and distribute two additional medicines from its oncology portfolio in Australia, New Zealand and Singapore, with an option to add further countries in the Asia-Pacific region. The expanded agreement will see new therapies axatilimab and retifanlimab added to the current partnered portfolio of Minjuvi
Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions
/PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and...
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: QGEN
Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: HALO
Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Incyte to Present at Upcoming Investor Conference
Incyte Gets FDA Approval for Zynyz in New Cancer Indication
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying
We recently published a list of 15 Small-Cap Healthcare Stocks Hedge Funds Are Buying. In this article, we are going to take a look at where Incyte Corporation (NASDAQ:INCY) stands against other small-cap healthcare stocks hedge funds are buying. The U.S. healthcare sector has performed better in 2025 compared to the broader market. After two […]
Mentions: BLK
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Incyte to Present at Upcoming Investor Conference
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
Here's What Key Metrics Tell Us About Incyte (INCY) Q1 Earnings
The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
NICE Lowered Revenue Outlook But Bullish Analyst Sees AI Momentum And Strong Cash Flow
Rosenblatt analyst Catharine Trebnick maintained NICE Ltd (NASDAQ:NICE) with a Buy rating and lowered the price forecast from $200 to $180 Thursday. Trebnick lowered her price forecast due to reduced fiscal 2025 and 2026 revenue estimates, citing macroeconomic uncertainty, which could further delay multinational Contact Center as a Service (CCaaS) deployments. The price target reflects ~3.4 times (from ~4 times) on the analyst’s revenue estimate of 7% Y/ Y in fiscal 2026. Also Read: Five9 Leans